Polpharma Biologics

Dr Konstantin Matentzoglu

Delegated Supervisory Board Member, Polpharma Biologics Group

“We care about being respectful and transparent”

Konstantin Matentzoglu is the CEO and a Member of the Board in Celonic Group. Passionate about advancing value-creating innovation in drug development, Dr Matentzoglu has been spearheading transformational turnarounds in various life science companies throughout his professional journey.
Parallel to voluntarily advising biotech start-ups, Konstantin sits on the board of Prediction Biosciences. Prior to joining Celonic, he provided commercial leadership to Ayoxxa Biosystems as Senior Vice President for Business Development.
Konstantin holds a Diploma in Biology from the University of Cologne, spent 3 years at the Netherlands Cancer Institute and received his PhD from the University of Constance.

Piotr Korycki

President of the Management Board, Polpharma Biologics S.A.

"We like to collaborate and can rely on each other"

Piotr Korycki is the President of the Management Board of Polpharma Biologics S.A. and the Managing Director of Polpharma Biologics Group. Piotr joined Mr Jerzy Staraks group of companies in early 2021 where he was involved in supervision of ZF Polpharma, Herbapol and others. In September 2021 he joined Polpharma Biologics. Prior to that Piotr was CEO and President of TVN SA - one of the largest and most successful media companies in Central and Eastern Europe, part of the global media corporation Discovery Inc. Before that, in 2012-2018 Piotr was CFO/COO of TVN with responsibility for areas including finance, HR, technology, investor relations and programs acquisitions. His career at TVN started in 2003 and during this time he was working on a significant number of financing and refinancing projects, business development, transformations and M&As as well as in TVN’s listing on stock exchange. Before TVN, Piotr was a manager at the Warsaw office of PricewaterhouseCoopers. Piotr has a masters degree in Finance from the Warsaw School of Economics (WSE) and continued his educational development at the International Institute for Management Development (IMD) in Lausanne, Switzerland, successfully completing the Program for Executive Development.

Mathieu Ballie

Chief Quality Officer, Polpharma Biologics Group

“Our patients expect and deserve high quality and innovative medicines”

Mathieu Ballié is a pharmacist from the University of Strasbourg, France. Fascinated about the engineering of biological drugs, he started his career in 2002 with Novartis France at a site manufacturing monoclonal antibodies. He was the site Quality Director when after 10 years, he moved to Switzerland to lead the Quality Assurance oversight for contract manufacturers for Novartis biologics, and later on for Bayer Healthcare Switzerland. Eager to be part of a new greenfield project, he relocated with his family to Singapore as Quality Director for the first biopharmaceutical plant built by Novartis in Asia contributing to facility approval by US FDA and EMA. Prior to joining Polpharma Biologics, Mathieu was in New Jersey, leading the US Quality organization for Advanced Accelerator Applications, a Novartis company, for manufacture and distribution of innovative radioligand therapy products.

Dr Adriana Kiędzierska-Mencfeld

Chief Integration Officer, Polpharma Biologics Group

“We work with dedication and find innovative solutions”

Dr Kiędzierska-Mencfeld has more than 15 years of experience in recombinant protein purification and expression in both prokaryotic and eukaryotic systems, and more than 10 years of experience in the development and GMP production of biosimilars. Prior to joining Polpharma Biologics as Production Director, Dr. Kiedzierska-Mencfeld spent four years as Head of GMP Production at the biotechnology firm Mabion S.A. She earned her Ph.D. in biochemistry from the Institute of Biochemistry and Molecular Biology at the University of Wroclaw, her MS in molecular biotechnology and biocatalysis from the Technical University of Wroclaw, and completed her masters thesis at the Technical University of Dresden.

Alexandra Moulson

Chief Strategy & Portfolio Officer, Polpharma Biologics Group

“We are experts in managing projects, transparent communicators and always deliver on our commitments”

Alex Moulson leads the consolidated development functions at Polpharma Biologics, overseeing Technical Development, Regulatory Affairs, Clinical Development, IP, Programs, PMO, Portfolio and Launch. The combined group oversees the progression of drug candidates from selection to launch, ensuring the required collaboration to get much needed medicines to patients. Alex is an experienced leader and strategist with a broad background in marketing, product development, business development, portfolio management and launch. She has over 18 years’ experience in pharmaceuticals, 8 years in originators, 8 years in biosimilars, and 2 years in generics. Alex is British, with Biochemistry and MBA degrees. She has a true passion to be part of a company generating high quality affordable medicines for patients. Her background in McKinsey, MorphoSys, and Sandoz as rituximab program lead and later head of Strategy and Novartis Collaborations sets her up perfectly to have impact at Polpharma Biologics as VP of Development.

Frederic Papp

Chief Technical Officer, Polpharma Biologics Group

“We work with dedication and find innovative solutions”

Frederic Papp is the General Manager Warsaw and CTO of Polpharma Biologics. He has over 25 years of professional experience. Prior to joining Polpharma Biologics, Frederic worked at Merck as Site Head of a Biotech Plant (Spain) as well as Head of Global Biotech Network Operations (Switzerland) alongside performing other senior global and local roles. He earned his MSc in Biology from the Technology University in Dijon (France).

Hannes Teissl

Chief Business Officer, Polpharma Biologics Group

"We care about delivering on our commitments"

Hannes Teissl is the Vice Chairman of Polpharma Biologics Group B.V. He has been with Polpharma Biologics since 2012 and was instrumental in establishing its foundations in Poland as well as the Netherlands (acquisition of Bioceros) and Switzerland (creation of Joint Venture Bioeq AG). Prior to joining Polpharma Biologics, Hannes has been an Executive Management Board Member at Sandoz, where he held several international management positions over 22 years (e.g. Global Head of Biopharmaceuticals, Global Head of M&A, CEO of Sandoz Germany).

Justyna Tyborowska

Chief People Officer, Polpharma Biologics Group

„Teamwork is the key to unlocking our collective potential and achieving greatness together"

Justyna joined Jerzy Starak's company group in early 2023. She sat on the Supervisory Boards of Polpharma ZF and Herbapol and served as Chief People & Culture Officer at some of the Group’s companies. She has been with Polpharma Biologics since December 2023. From 2016 to 2022, she worked as SVP/Chief HR Officer for an international medical network, where she built and managed HR structures in 15 European countries. She created and implemented patient experience programs and was involved in building company value through acquisitions, participating in due diligence processes and post-acquisition integrations in Western Europe and CEE. Previously, as Executive Director, she worked at Russell Reynolds Associates, an executive search firm. From 1999 to 2014, at Tech Data - a U.S.-based technology distribution company, as Regional HR Director, she managed the Nordic and CEE HR teams and, as Culture Change Leader, led one of the streams in an international strategic sales transformation program. She started her career as a Senior Management Consultant at KPMG, where she worked on Human Capital projects. She is a graduate of the University of Warsaw with a master's degree in psychology and a specialization in clinical psychology.

Jakub Walkowiak

Chief Financial Officer, Polpharma Biologics Group

“We are passionate about getting safe and effective medicines to patients”

Jakub Walkowiak is the Chief Financial Officer of the Polpharma Biologics Group. Jakub joined Mr.Jerzy Starak’s group of companies in 2017, first working in the Strategic Investments team of Polpharma and then switching his focus increasingly towards the Polpharma Biologics business. Earlier, Jakub worked in the Warsaw office of an investment banking boutique headquartered in Vienna, where he was responsible for leading Mergers & Acquisitions as well as consultancy projects, predominantly for institutional investors. He has an extensive background in finance, strategy and business development, as well as experience in consulting.

Industry leading team

Jerzy Starak

Supervisory Board Polpharma Biologics Group

Leaders Polpharma Biologics Group

Site Heads

Let’s collaborate and deliver quality biosimilars together.

Emmanuelle Lepine

Dr Joerg Windisch

Dr Michel Cup

Dr Konstantin Matentzoglu

Gertjan Noordermeer

Dr Konstantin Matentzoglu

Piotr Korycki

Mathieu Ballie

Dr Adriana Kiędzierska-Mencfeld

Alexandra Moulson

Frederic Papp

Hannes Teissl

Justyna Tyborowska

Jakub Walkowiak

Athos Bonanomi

Dr Adriana Kiędzierska-Mencfeld

Jonathan Robinson